FY2027 Earnings Estimate for CRL Issued By Zacks Research

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at Zacks Research issued their FY2027 EPS estimates for Charles River Laboratories International in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst R. Department anticipates that the medical research company will post earnings per share of $11.39 for the year. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 earnings per share.

A number of other research firms have also weighed in on CRL. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price objective for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Morgan Stanley dropped their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Robert W. Baird dropped their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $167.03 on Friday. The firm has a market cap of $8.54 billion, a PE ratio of 1,113.55, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The business has a 50 day moving average price of $168.35 and a 200-day moving average price of $185.07.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after acquiring an additional 335,658 shares in the last quarter. State Street Corp increased its holdings in shares of Charles River Laboratories International by 2.0% during the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after acquiring an additional 14,787 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).